Stages

Premature Ovarian Insufficiency

Creator: Dr Nadira Awal
Published: 2026-01-15

Early menopause under 40 — diagnosis, treatment and long-term care.

By Dr Nadira AwalBMS Specialist2 min readMedically reviewed 9 July 2026

Single small white daisy in a slim clear glass on cream linen

POI affects around 1 in 100 women under 40. Diagnosis matters because HRT (usually until at least the natural age of menopause) protects the heart, bones and brain.

Premature Ovarian Insufficiency (POI) is menopause before the age of 40, and it affects roughly 1 in 100 women. It is not the same as 'early menopause' between 40 and 45 — POI is a distinct diagnosis with distinct long-term health implications. Because these women have decades of low oestrogen ahead of them, POI is one of the areas where prompt, correct treatment matters most. Sadly, it is also frequently missed, misdiagnosed or under-treated in general practice.

How POI is diagnosed

Absent or irregular periods for at least 4 months in a woman under 40.
Two elevated FSH readings (typically >25 IU/L) taken 4–6 weeks apart.
Thyroid function, prolactin, karyotype and autoimmune screens (adrenal antibodies, TPO antibodies) are usually done to look for underlying causes.
In around three-quarters of cases no specific cause is found ('idiopathic' POI).
Known causes include autoimmune disease, genetic conditions (Turner syndrome, Fragile X premutation), chemotherapy, radiotherapy and bilateral oophorectomy.

Why treatment matters more, not less, in POI

Bone density loss is rapid and significant without oestrogen replacement — osteoporosis risk is high.
Cardiovascular disease risk rises substantially at a young age.
Cognitive and mood impact can be profound — depression rates are markedly higher.
Life expectancy is modestly reduced in untreated POI, largely from cardiovascular disease.
Vaginal, urinary and sexual health suffer without oestrogen.

A young woman speaking with a specialist doctor — In POI, higher doses of body-identical HRT are usually needed until at least age 51.

Treatment principles

HRT (or the combined pill in some cases) is recommended until at least age 51 — the natural age of menopause — and often longer.
Doses are typically higher than for older women, reflecting the need to replace what the ovaries would normally be making.
Body-identical transdermal oestrogen plus micronised progesterone (or Mirena) is the modern standard.
The combined pill can be an alternative for younger women who prefer it, though it does not provide the same physiological replacement as HRT.
Fertility may be intermittent — POI does not always mean sterility, and 5–10% of women conceive spontaneously after diagnosis. Contraception may still be needed.

Extra support that helps

Psychological support — POI is a grief as much as a diagnosis, particularly for women who had hoped to have (more) children.
Fertility counselling and, where appropriate, discussion of egg donation.
Peer support through the Daisy Network charity (daisynetwork.org).
Bone protection: adequate calcium, vitamin D, resistance training and a baseline DXA scan.
Cardiovascular risk assessment and management.

What to watch for long-term

Annual review of HRT dose, symptoms and quality of life.
DXA scan at diagnosis and periodically thereafter.
Blood pressure, cholesterol and glucose monitoring.
Screening for associated autoimmune conditions (thyroid, adrenal, diabetes, coeliac).

Key takeaway

POI deserves specialist input from the start. The message from BMS, NICE and every major menopause society is unambiguous: replace the hormones these women would otherwise have made, and continue at least until the natural age of menopause.

How Dr Awal approaches this in clinic

Every consultation starts with your full story — symptoms, cycle, medical history, family history and what you've already tried. From there we look at whether hormonal treatment, non-hormonal options, lifestyle changes or a combination will give you the best result, and we tailor the plan to your age, risk factors and preferences.

A detailed 60 minute first appointment — no rushed 10-minute slots.
Evidence-based recommendations aligned with NICE NG23 and BMS guidance.
Body-identical HRT considered first-line where appropriate.
Shared-care letters sent to your NHS GP so treatment can continue affordably.
Follow-up at 3 months to fine-tune your regimen and address side effects.
Ongoing annual reviews so your plan evolves with you.

Common questions we hear about this

Do I need to be at a certain age to be seen?

No. We see women in early perimenopause (often late 30s and 40s), through post-menopause and beyond. Age alone doesn't decide whether treatment is right — symptoms, health history and goals do.

Will my GP continue the prescription?

In most cases yes. After your consultation we send a detailed shared-care letter with the diagnosis, treatment plan and rationale so your NHS GP can prescribe on the NHS. Not every practice accepts shared care — we'll discuss this in your appointment.

What if I've tried HRT before and it didn't suit me?

Very common — often the type, dose or route wasn't right rather than HRT itself. We review what you've tried, why it didn't work, and adjust accordingly. Many women who thought HRT wasn't for them do well on a different preparation.

How long will I need to stay on treatment?

There is no set upper time limit for HRT. Current BMS and NICE guidance supports continuing HRT for as long as the benefits outweigh the risks for you personally. We review this together every year so you stay in control of the decision.

Where do you see patients?

All consultations at Pause and Co Healthcare are conducted securely via video, allowing us to support patients anywhere in the UK. Prescriptions and shared care arrangements are managed in the same way, regardless of your location.

About the author

Dr Nadira Awal is a British Menopause Society Advanced Menopause Specialist with 15+ years' NHS and private experience. She holds the BMS Advanced Certificate in Menopause Care, sits on the BMS Programme Planning Group, and advises the UK Government Menopause Strategy Group. Read her full profile.

Sources & further reading

General information only — not a substitute for personalised medical advice. Always speak to your GP or a menopause specialist about your own situation.

Talk it through